Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Alzheimer's Disease

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 131 articles:
HTML format



Single Articles


    January 2022
  1. KIM HJ, Ryou JH, Choi KT, Kim SM, et al
    Deficits in color detection in patients with Alzheimer disease.
    PLoS One. 2022;17:e0262226.
    PubMed     Abstract available


  2. SHABBIR U, Tyagi A, Ham HJ, Oh DH, et al
    Comprehensive profiling of bioactive compounds in germinated black soybeans via UHPLC-ESI-QTOF-MS/MS and their anti-Alzheimer's activity.
    PLoS One. 2022;17:e0263274.
    PubMed     Abstract available


  3. LEACH JM, Edwards LJ, Kana R, Visscher K, et al
    The spike-and-slab elastic net as a classification tool in Alzheimer's disease.
    PLoS One. 2022;17:e0262367.
    PubMed     Abstract available


  4. JUNG NY, Kim HS, Kim ES, Jeon S, et al
    Serum progranulin is not associated with rs5848 polymorphism in Korean patients with neurodegenerative diseases.
    PLoS One. 2022;17:e0261007.
    PubMed     Abstract available


  5. HUANG YC, Hsu SM, Shie FS, Shiao YJ, et al
    Reduced mitochondria membrane potential and lysosomal acidification are associated with decreased oligomeric Abeta degradation induced by hyperglycemia: A study of mixed glia cultures.
    PLoS One. 2022;17:e0260966.
    PubMed     Abstract available


  6. QUERFURTH H, Marshall J, Parang K, Rioult-Pedotti MS, et al
    A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro.
    PLoS One. 2022;17:e0261696.
    PubMed     Abstract available


  7. LEE JI, Lim JS, Hong JH, Kim S, et al
    Selective neurodegeneration of the hippocampus caused by chronic cerebral hypoperfusion: F-18 FDG PET study in rats.
    PLoS One. 2022;17:e0262224.
    PubMed     Abstract available


  8. SADLEIR KR, Popovic J, Khatri A, Vassar R, et al
    Oral nimodipine treatment has no effect on amyloid pathology or neuritic dystrophy in the 5XFAD mouse model of amyloidosis.
    PLoS One. 2022;17:e0263332.
    PubMed     Abstract available


  9. REHMAN S, Ali Ashfaq U, Sufyan M, Shahid I, et al
    The Insight of In Silico and In Vitro evaluation of Beta vulgaris phytochemicals against Alzheimer's disease targeting acetylcholinesterase.
    PLoS One. 2022;17:e0264074.
    PubMed     Abstract available


  10. SUZUKI Y, Suzuki M, Shigenobu K, Shinosaki K, et al
    A prospective multicenter validation study of a machine learning algorithm classifier on quantitative electroencephalogram for differentiating between dementia with Lewy bodies and Alzheimer's dementia.
    PLoS One. 2022;17:e0265484.
    PubMed     Abstract available


  11. ZHANG Q, Yang X, Sun Z
    Classification of Alzheimer's disease progression based on sMRI using gray matter volume and lateralization index.
    PLoS One. 2022;17:e0262722.
    PubMed     Abstract available


  12. MARTIZ RM, Patil SM, Ramu R, M K J, et al
    Discovery of novel benzophenone integrated derivatives as anti-Alzheimer's agents targeting presenilin-1 and presenilin-2 inhibition: A computational approach.
    PLoS One. 2022;17:e0265022.
    PubMed     Abstract available


  13. PAYNE M, Manera V, Robert P, Vandersteen C, et al
    Olfactory identification disorders due to Alzheimer's disease: A new test from France to Quebec.
    PLoS One. 2022;17:e0265764.
    PubMed     Abstract available


  14. IOHAN LDCC, Lambert JC, Costa MR
    Analysis of modular gene co-expression networks reveals molecular pathways underlying Alzheimer's disease and progressive supranuclear palsy.
    PLoS One. 2022;17:e0266405.
    PubMed     Abstract available


  15. SARIS IMJ, Aghajani M, Jongs N, Reus LM, et al
    Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and alzheimer's disease patients.
    PLoS One. 2022;17:e0263769.
    PubMed     Abstract available


  16. MOUSA D, Zayed N, Yassine IA
    Alzheimer disease stages identification based on correlation transfer function system using resting-state functional magnetic resonance imaging.
    PLoS One. 2022;17:e0264710.
    PubMed     Abstract available


  17. KORTHAUER LE, Giugliano RP, Guo J, Sabatine MS, et al
    No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab.
    PLoS One. 2022;17:e0266615.
    PubMed     Abstract available


  18. YOUSEFZADEH-NOWSHAHR E, Winter G, Bohn P, Kneer K, et al
    Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting.
    PLoS One. 2022;17:e0266906.
    PubMed     Abstract available


  19. UCHIYAMA S, Kamoi F, Tanaka M, Joko I, et al
    What is the subtype of dementia in patients with fragility hip fracture?
    PLoS One. 2022;17:e0265636.
    PubMed     Abstract available


  20. ABD EL-RAHMAN SS, Fayed HM
    Improved cognition impairment by activating cannabinoid receptor type 2: Modulating CREB/BDNF expression and impeding TLR-4/NFkappaBp65/M1 microglia signaling pathway in D-galactose-injected ovariectomized rats.
    PLoS One. 2022;17:e0265961.
    PubMed     Abstract available


  21. SOLIMAN MG, Davies HA, Sharkey J, Levy R, et al
    Development of amyloid beta gold nanorod aggregates as optoacoustic probes.
    PLoS One. 2022;17:e0259608.
    PubMed     Abstract available


  22. BANACK SA, Stark AC, Cox PA
    A possible blood plasma biomarker for early-stage Alzheimer's disease.
    PLoS One. 2022;17:e0267407.
    PubMed     Abstract available


  23. NAITO N, Hirosawa T, Tsubomoto M, Miyagishi Y, et al
    Prominent gamma band activity during visual motion perception in early-stage Alzheimer's disease.
    PLoS One. 2022;17:e0266693.
    PubMed     Abstract available


  24. SOUDY R, Kimura R, Fu W, Patel A, et al
    Extracellular vesicles enriched with amylin receptor are cytoprotective against the Ass toxicity in vitro.
    PLoS One. 2022;17:e0267164.
    PubMed     Abstract available


  25. HERNANDEZ M, Ramon-Julvez U, Ferraz F
    Explainable AI toward understanding the performance of the top three TADPOLE Challenge methods in the forecast of Alzheimer's disease diagnosis.
    PLoS One. 2022;17:e0264695.
    PubMed     Abstract available


  26. PHAM H, Yin T, D'Adamio L
    Initial assessment of the spatial learning, reversal, and sequencing task capabilities of knock-in rats with humanizing mutations in the Abeta-coding region of App.
    PLoS One. 2022;17:e0263546.
    PubMed     Abstract available


  27. ANDRADE JM, Pachar P, Trujillo L, Cartuche L, et al
    Suillin: A mixed-type acetylcholinesterase inhibitor from Suillus luteus which is used by Saraguros indigenous, southern Ecuador.
    PLoS One. 2022;17:e0268292.
    PubMed     Abstract available


  28. CANNAVO C, Cleverley K, Maduro C, Mumford P, et al
    Endosomal structure and APP biology are not altered in a preclinical mouse cellular model of Down syndrome.
    PLoS One. 2022;17:e0262558.
    PubMed     Abstract available


  29. ALI M, Sung YJ, Wang F, Fernandez MV, et al
    Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk.
    PLoS One. 2022;17:e0267298.
    PubMed     Abstract available


  30. GARCIA MARIN ID, Camarillo Lopez RH, Martinez OA, Padilla-Martinez II, et al
    New compounds from heterocyclic amines scaffold with multitarget inhibitory activity on Abeta aggregation, AChE, and BACE1 in the Alzheimer disease.
    PLoS One. 2022;17:e0269129.
    PubMed     Abstract available


  31. SELF W, Awwad K, Savaryn JP, Schulz M, et al
    An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS.
    PLoS One. 2022;17:e0269157.
    PubMed     Abstract available


  32. ZAMANI J, Sadr A, Javadi AH
    Classification of early-MCI patients from healthy controls using evolutionary optimization of graph measures of resting-state fMRI, for the Alzheimer's disease neuroimaging initiative.
    PLoS One. 2022;17:e0267608.
    PubMed     Abstract available


  33. LEE H, Kim HK, Kim B, Han K, et al
    Augmented risk of dementia in hypertrophic cardiomyopathy: A propensity score matching analysis using the nationwide cohort.
    PLoS One. 2022;17:e0269911.
    PubMed     Abstract available


  34. FLO BK, Matziorinis AM, Skouras S, Sudmann TT, et al
    Study protocol for the Alzheimer and music therapy study: An RCT to compare the efficacy of music therapy and physical activity on brain plasticity, depressive symptoms, and cognitive decline, in a population with and at risk for Alzheimer's disease.
    PLoS One. 2022;17:e0270682.
    PubMed     Abstract available


  35. ALI SK, Ali RH
    Effects of antidiabetic agents on Alzheimer's disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin.
    PLoS One. 2022;17:e0271138.
    PubMed     Abstract available


  36. CUADRADO F, Antoli A, Fernandez-Calvo B
    The effect of framing on attitudes towards Alzheimer's disease. A comparative study between younger and older adults.
    PLoS One. 2022;17:e0270959.
    PubMed     Abstract available


  37. KANNAPPAN B, Gunasekaran TI, Te Nijenhuis J, Gopal M, et al
    Polygenic score for Alzheimer's disease identifies differential atrophy in hippocampal subfield volumes.
    PLoS One. 2022;17:e0270795.
    PubMed     Abstract available


  38. VIDONI ED, Morris JK, Palmer JA, Li Y, et al
    Dementia risk and dynamic response to exercise: A non-randomized clinical trial.
    PLoS One. 2022;17:e0265860.
    PubMed     Abstract available


  39. KHASAWNEH RR, Abu-El-Rub E, Alzu'bi A, Abdelhady GT, et al
    Corpus callosum anatomical changes in Alzheimer patients and the effect of acetylcholinesterase inhibitors on corpus callosum morphometry.
    PLoS One. 2022;17:e0269082.
    PubMed     Abstract available


  40. BAJIC VP, Salhi A, Lakota K, Radovanovic A, et al
    DES-Amyloidoses "Amyloidoses through the looking-glass": A knowledgebase developed for exploring and linking information related to human amyloid-related diseases.
    PLoS One. 2022;17:e0271737.
    PubMed     Abstract available


  41. BRAIN J, Tully PJ, Turnbull D, Tang E, et al
    Risk factors for dementia in the context of cardiovascular disease: A protocol of an overview of reviews.
    PLoS One. 2022;17:e0271611.
    PubMed     Abstract available


  42. TEJADA MORENO JA, Villegas Lanau A, Madrigal Zapata L, Baena Pineda AY, et al
    Mutations in SORL1 and MTHFDL1 possibly contribute to the development of Alzheimer's disease in a multigenerational Colombian Family.
    PLoS One. 2022;17:e0269955.
    PubMed     Abstract available


  43. SINCLAIR P, Kabbani N
    Nicotinic receptor components of amyloid beta 42 proteome regulation in human neural cells.
    PLoS One. 2022;17:e0270479.
    PubMed     Abstract available


  44. FAVERO F, Barberis E, Gagliardi M, Espinoza S, et al
    A Metabologenomic approach reveals alterations in the gut microbiota of a mouse model of Alzheimer's disease.
    PLoS One. 2022;17:e0273036.
    PubMed     Abstract available


  45. ACQUARELLI J, van Laarhoven T, Postma GJ, Jansen JJ, et al
    Convolutional neural networks to predict brain tumor grades and Alzheimer's disease with MR spectroscopic imaging data.
    PLoS One. 2022;17:e0268881.
    PubMed     Abstract available


  46. NAMCHAIW P, Bunreangsri P, Eiamcharoen P, Eiamboonsert S, et al
    An in vitro workflow of neuron-laden agarose-laminin hydrogel for studying small molecule-induced amyloidogenic condition.
    PLoS One. 2022;17:e0273458.
    PubMed     Abstract available


  47. FANG Y, Doyle MF, Chen J, Alosco ML, et al
    Association between inflammatory biomarkers and cognitive aging.
    PLoS One. 2022;17:e0274350.
    PubMed     Abstract available


  48. HLYNIALUK C, Kemper L, Leinonen-Wright K, Petersen RC, et al
    Caspase-2 mRNA levels are not elevated in mild cognitive impairment, Alzheimer's disease, Huntington's disease, or Lewy Body dementia.
    PLoS One. 2022;17:e0274784.
    PubMed     Abstract available


  49. WEI Y, Heun-Johnson H, Tysinger B
    Using dynamic microsimulation to project cognitive function in the elderly population.
    PLoS One. 2022;17:e0274417.
    PubMed     Abstract available


  50. HOHBERGER B, Pruss H, Mardin C, Lammer R, et al
    Glaucoma and Alzheimer: Neurodegenerative disorders show an adrenergic dysbalance.
    PLoS One. 2022;17:e0272811.
    PubMed     Abstract available


  51. SUGIOKA J, Suzumura S, Kuno K, Kizuka S, et al
    Relationship between finger movement characteristics and brain voxel-based morphometry.
    PLoS One. 2022;17:e0269351.
    PubMed     Abstract available


  52. WONG J, Steyn JS, Pienaar IS, Elson JL, et al
    Mitochondrial DNA population variation is not associated with Alzheimer's in the Japanese population: A consistent finding across global populations.
    PLoS One. 2022;17:e0276169.
    PubMed     Abstract available


  53. SU S, Esparza TJ, Brody DL
    Selection of single domain anti-transferrin receptor antibodies for blood-brain barrier transcytosis using a neurotensin based assay and histological assessment of target engagement in a mouse model of Alzheimer's related amyloid-beta pathology.
    PLoS One. 2022;17:e0276107.
    PubMed     Abstract available


  54. KANNAPPAN B, Te Nijenhuis J, Choi YY, Lee JJ, et al
    Can hippocampal subfield measures supply information that could be used to improve the diagnosis of Alzheimer's disease?
    PLoS One. 2022;17:e0275233.
    PubMed     Abstract available


  55. NASIRI M, Moayedfar S, Purmohammad M, Ghasisin L, et al
    Investigating sentence processing and working memory in patients with mild Alzheimer and elderly people.
    PLoS One. 2022;17:e0266552.
    PubMed     Abstract available


  56. ZARETSKY DV, Zaretskaia MV, Molkov YI
    Patients with Alzheimer's disease have an increased removal rate of soluble beta-amyloid-42.
    PLoS One. 2022;17:e0276933.
    PubMed     Abstract available


  57. RANTS'O TA, van Greunen DG, van der Westhuizen CJ, Riley DL, et al
    The in silico and in vitro analysis of donepezil derivatives for Anopheles acetylcholinesterase inhibition.
    PLoS One. 2022;17:e0277363.
    PubMed     Abstract available


  58. TOLEDO JB, Rashid T, Liu H, Launer L, et al
    SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline.
    PLoS One. 2022;17:e0276392.
    PubMed     Abstract available


  59. KARAMAN BK, Mormino EC, Sabuncu MR
    Machine learning based multi-modal prediction of future decline toward Alzheimer's disease: An empirical study.
    PLoS One. 2022;17:e0277322.
    PubMed     Abstract available


  60. BARTELS SL, Shaaban CE, Brum WS, Welikovitch LA, et al
    Impact of the COVID-19 pandemic on early career dementia researchers: A global online survey.
    PLoS One. 2022;17:e0277470.
    PubMed     Abstract available


    January 2021
  61. PENNER G, Lecocq S, Chopin A, Vedoya X, et al
    Aptamarker prediction of brain amyloid-beta status in cognitively normal individuals at risk for Alzheimer's disease.
    PLoS One. 2021;16:e0243902.
    PubMed     Abstract available


  62. VIDONI ED, Morris JK, Watts A, Perry M, et al
    Effect of aerobic exercise on amyloid accumulation in preclinical Alzheimer's: A 1-year randomized controlled trial.
    PLoS One. 2021;16:e0244893.
    PubMed     Abstract available


  63. MEGHDADI AH, Stevanovic Karic M, McConnell M, Rupp G, et al
    Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment.
    PLoS One. 2021;16:e0244180.
    PubMed     Abstract available


  64. TOKUMITSU K, Yasui-Furukori N, Takeuchi J, Yachimori K, et al
    The combination of MMSE with VSRAD and eZIS has greater accuracy for discriminating mild cognitive impairment from early Alzheimer's disease than MMSE alone.
    PLoS One. 2021;16:e0247427.
    PubMed     Abstract available


  65. CHELLAPPA RC, Lukose B, Rani P
    Correction: G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer's disease pathology.
    PLoS One. 2021;16:e0248252.
    PubMed     Abstract available


  66. VOIGT RM, Raeisi S, Yang J, Leurgans S, et al
    Systemic brain derived neurotrophic factor but not intestinal barrier integrity is associated with cognitive decline and incident Alzheimer's disease.
    PLoS One. 2021;16:e0240342.
    PubMed     Abstract available


  67. GJERUM L, Andersen BB, Bruun M, Simonsen AH, et al
    Comparison of the clinical impact of 2-[18F]FDG-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer's disease.
    PLoS One. 2021;16:e0248413.
    PubMed     Abstract available


  68. ZABEL P, Kaluzny JJ, Zabel K, Kaluzna M, et al
    Quantitative assessment of retinal thickness and vessel density using optical coherence tomography angiography in patients with Alzheimer's disease and glaucoma.
    PLoS One. 2021;16:e0248284.
    PubMed     Abstract available


  69. BAHADO-SINGH RO, Vishweswaraiah S, Aydas B, Yilmaz A, et al
    Artificial intelligence and leukocyte epigenomics: Evaluation and prediction of late-onset Alzheimer's disease.
    PLoS One. 2021;16:e0248375.
    PubMed     Abstract available


  70. KIM D, Lee JH, Kim HY, Shin J, et al
    Correction: Fluorescent indolizine derivative YI-13 detects amyloid-beta monomers, dimers, and plaques in the brain of 5XFAD Alzheimer transgenic mouse model.
    PLoS One. 2021;16:e0250194.
    PubMed     Abstract available


  71. TSUNEISHI M, Yamamoto T, Yamaguchi T, Kodama T, et al
    Association between number of teeth and Alzheimer's disease using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
    PLoS One. 2021;16:e0251056.
    PubMed     Abstract available


  72. VELAZQUEZ M, Lee Y
    Random forest model for feature-based Alzheimer's disease conversion prediction from early mild cognitive impairment subjects.
    PLoS One. 2021;16:e0244773.
    PubMed     Abstract available


  73. MCCORMICK JW, Ammerman L, Chen G, Vogel PD, et al
    Transport of Alzheimer's associated amyloid-beta catalyzed by P-glycoprotein.
    PLoS One. 2021;16:e0250371.
    PubMed     Abstract available


  74. WEN LY, Wan L, Lai JN, Chen CS, et al
    Increased risk of Alzheimer's disease among patients with age-related macular degeneration: A nationwide population-based study.
    PLoS One. 2021;16:e0250440.
    PubMed     Abstract available


  75. STOJANOVIC F, Taktek M, Khieu NH, Huang J, et al
    NMR analysis of the correlation of metabolic changes in blood and cerebrospinal fluid in Alzheimer model male and female mice.
    PLoS One. 2021;16:e0250568.
    PubMed     Abstract available


  76. ZHENG C, Xu R
    Molecular subtyping of Alzheimer's disease with consensus non-negative matrix factorization.
    PLoS One. 2021;16:e0250278.
    PubMed     Abstract available


  77. JIANG X, Howard JH Jr, Rebeck GW, Turner RS, et al
    Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimer's disease.
    PLoS One. 2021;16:e0252958.
    PubMed     Abstract available


  78. ZHANG J, Zhang Y, Zou J, Cao F, et al
    A meta-analysis of cohort studies: Traumatic brain injury and risk of Alzheimer's Disease.
    PLoS One. 2021;16:e0253206.
    PubMed     Abstract available


  79. FUKUI K, Kimura S, Kato Y, Kohno M, et al
    Effects of far infrared light on Alzheimer's disease-transgenic mice.
    PLoS One. 2021;16:e0253320.
    PubMed     Abstract available


  80. WENG J, Zhao G, Weng L, Guan J, et al
    Aspirin using was associated with slower cognitive decline in patients with Alzheimer's disease.
    PLoS One. 2021;16:e0252969.
    PubMed     Abstract available


  81. MINICUCCI J, Alfond M, Demuro A, Gerberry D, et al
    Quantifying the dose-dependent impact of intracellular amyloid beta in a mathematical model of calcium regulation in xenopus oocyte.
    PLoS One. 2021;16:e0246116.
    PubMed     Abstract available


  82. TOPPING M, Kim J, Fletcher J
    Geographic variation in Alzheimer's disease mortality.
    PLoS One. 2021;16:e0254174.
    PubMed     Abstract available


  83. RHEW SH, Kravchenko J, Lyerly HK
    Exposure to low-dose ambient fine particulate matter PM2.5 and Alzheimer's disease, non-Alzheimer's dementia, and Parkinson's disease in North Carolina.
    PLoS One. 2021;16:e0253253.
    PubMed     Abstract available


  84. LIBOWITZ MR, Wei K, Tran T, Chu K, et al
    Regional brain volumes relate to Alzheimer's disease cerebrospinal fluid biomarkers and neuropsychometry: A cross-sectional, observational study.
    PLoS One. 2021;16:e0254332.
    PubMed     Abstract available


  85. HUI J, Zhao Y, Yu S, Liu J, et al
    Detection of retinal changes with optical coherence tomography angiography in mild cognitive impairment and Alzheimer's disease patients: A meta-analysis.
    PLoS One. 2021;16:e0255362.
    PubMed     Abstract available


  86. LEE SH, Chen YH, Chien CC, Yan YH, et al
    Three month inhalation exposure to low-level PM2.5 induced brain toxicity in an Alzheimer's disease mouse model.
    PLoS One. 2021;16:e0254587.
    PubMed     Abstract available


  87. SAKUTA S, Hashimoto M, Ikeda M, Koyama A, et al
    Clinical features of behavioral symptoms in patients with semantic dementia: Does semantic dementia cause autistic traits?
    PLoS One. 2021;16:e0247184.
    PubMed     Abstract available


  88. PIERSSON AD, Ibrahim B, Suppiah S, Mohamad M, et al
    Multiparametric MRI for the improved diagnostic accuracy of Alzheimer's disease and mild cognitive impairment: Research protocol of a case-control study design.
    PLoS One. 2021;16:e0252883.
    PubMed     Abstract available


  89. WICKLAND DP, Ren Y, Sinnwell JP, Reddy JS, et al
    Impact of variant-level batch effects on identification of genetic risk factors in large sequencing studies.
    PLoS One. 2021;16:e0249305.
    PubMed     Abstract available


  90. VESPA A, Spatuzzi R, Fabbietti P, Penna M, et al
    Association between care burden, depression and personality traits in Alzheimer's caregiver: A pilot study.
    PLoS One. 2021;16:e0251813.
    PubMed     Abstract available


  91. BARTL M, Dakna M, Galasko D, Hutten SJ, et al
    Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.
    PLoS One. 2021;16:e0257372.
    PubMed     Abstract available


  92. KOLINGER GD, Vallez Garcia D, Willemsen ATM, Reesink FE, et al
    Amyloid burden quantification depends on PET and MR image processing methodology.
    PLoS One. 2021;16:e0248122.
    PubMed     Abstract available


  93. FERNANDEZ-BLAZQUEZ MA, Del Ser T, Frades-Payo B, Avila-Villanueva M, et al
    MADRID+90 study on factors associated with longevity: Study design and preliminary data.
    PLoS One. 2021;16:e0251796.
    PubMed     Abstract available


  94. CALDERON C, Beyle C, Veliz-Garcia O, Bekios-Calfa J, et al
    Psychometric properties of Addenbrooke's Cognitive Examination III (ACE-III): An item response theory approach.
    PLoS One. 2021;16:e0251137.
    PubMed     Abstract available


  95. AKBOR MM, Kurosawa N, Nakayama H, Nakatani A, et al
    Polymorphic SERPINA3 prolongs oligomeric state of amyloid beta.
    PLoS One. 2021;16:e0248027.
    PubMed     Abstract available


  96. PARWEEN F, Hossain MS, Singh KP, Gupta RD, et al
    Association between human paraoxonase 2 protein and efficacy of acetylcholinesterase inhibiting drugs used against Alzheimer's disease.
    PLoS One. 2021;16:e0258879.
    PubMed     Abstract available


  97. NOGUCHI-SHINOHARA M, Koike M, Morise H, Kudo K, et al
    MEG activity of the dorsolateral prefrontal cortex during optic flow stimulations detects mild cognitive impairment due to Alzheimer's disease.
    PLoS One. 2021;16:e0259677.
    PubMed     Abstract available


  98. BAILEY DK, Clark W, Kosman DJ
    The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells.
    PLoS One. 2021;16:e0254794.
    PubMed     Abstract available


  99. WU Y, Whittaker HT, Noy S, Cleverley K, et al
    The effects of Cstb duplication on APP/amyloid-beta pathology and cathepsin B activity in a mouse model.
    PLoS One. 2021;16:e0242236.
    PubMed     Abstract available


  100. JIANG H, Esparza TJ, Kummer TT, Brody DL, et al
    Unbiased high-content screening reveals Abeta- and tau-independent synaptotoxic activities in human brain homogenates from Alzheimer's patients and high-pathology controls.
    PLoS One. 2021;16:e0259335.
    PubMed     Abstract available


  101. JIANG J, Liu H, Wang Z, Tian H, et al
    Electroacupuncture could balance the gut microbiota and improve the learning and memory abilities of Alzheimer's disease animal model.
    PLoS One. 2021;16:e0259530.
    PubMed     Abstract available


  102. CZAPSKI GA, Cieslik M, Bialopiotrowicz E, Lukiw WJ, et al
    Down-regulation of cyclin D2 in amyloid beta toxicity, inflammation, and Alzheimer's disease.
    PLoS One. 2021;16:e0259740.
    PubMed     Abstract available


  103. GRUNDMAN J, Spencer B, Sarsoza F, Rissman RA, et al
    Transcriptome analyses reveal tau isoform-driven changes in transposable element and gene expression.
    PLoS One. 2021;16:e0251611.
    PubMed     Abstract available


  104. WU X, Peng C, Nelson PT, Cheng Q, et al
    Random forest-integrated analysis in AD and LATE brain transcriptome-wide data to identify disease-specific gene expression.
    PLoS One. 2021;16:e0256648.
    PubMed     Abstract available


  105. SHIMODA A, Li Y, Hayashi H, Kondo N, et al
    Dementia risks identified by vocal features via telephone conversations: A novel machine learning prediction model.
    PLoS One. 2021;16:e0253988.
    PubMed     Abstract available


  106. XIN XY, Lai ZH, Ding KQ, Zeng LL, et al
    Angiotensin-converting enzyme polymorphisms AND Alzheimer's disease susceptibility: An updated meta-analysis.
    PLoS One. 2021;16:e0260498.
    PubMed     Abstract available


  107. HIRALDO-GONZALEZ L, Trillo-Contreras JL, Garcia-Miranda P, Pineda-Sanchez R, et al
    Evaluation of aquaporins in the cerebrospinal fluid in patients with idiopathic normal pressure hydrocephalus.
    PLoS One. 2021;16:e0258165.
    PubMed     Abstract available


  108. RICHARD P, Kozlowski L, Guillorit H, Garnier P, et al
    Queuine, a bacterial-derived hypermodified nucleobase, shows protection in in vitro models of neurodegeneration.
    PLoS One. 2021;16:e0253216.
    PubMed     Abstract available


  109. SCHOBER J, Polina J, Walters F, Scott N, et al
    NNC 26-9100 increases Abeta1-42 phagocytosis, inhibits nitric oxide production and decreases calcium in BV2 microglia cells.
    PLoS One. 2021;16:e0254242.
    PubMed     Abstract available


  110. KAMAL S, Park I, Kim YJ, Kim YJ, et al
    Alteration of the corpus callosum in patients with Alzheimer's disease: Deep learning-based assessment.
    PLoS One. 2021;16:e0259051.
    PubMed     Abstract available


  111. ZUELKE AE, Riedel-Heller SG, Wittmann F, Pabst A, et al
    Gender-specific design and effectiveness of non-pharmacological interventions against cognitive decline and dementia-protocol for a systematic review and meta-analysis.
    PLoS One. 2021;16:e0256826.
    PubMed     Abstract available


  112. KAYA-TILKI E, Dikmen M
    Neuroprotective effects of some epigenetic modifying drugs' on Chlamydia pneumoniae-induced neuroinflammation: A novel model.
    PLoS One. 2021;16:e0260633.
    PubMed     Abstract available


    January 2020
  113. BOUBAKRI A, Leri M, Bucciantini M, Najjaa H, et al
    Allium roseum L. extract inhibits amyloid beta aggregation and toxicity involved in Alzheimer's disease.
    PLoS One. 2020;15:e0223815.
    PubMed     Abstract available


  114. MITSUMORI R, Sakaguchi K, Shigemizu D, Mori T, et al
    Lower DNA methylation levels in CpG island shores of CR1, CLU, and PICALM in the blood of Japanese Alzheimer's disease patients.
    PLoS One. 2020;15:e0239196.
    PubMed     Abstract available


  115. RONCERO C, Nikelski J, Probst S, Fernandez A, et al
    The semantic storage loss score: An Algorithm for measuring an individual's level of semantic storage loss due to temporal lobe damage in neurodegenerative disease.
    PLoS One. 2020;15:e0235810.
    PubMed     Abstract available


  116. GUPTA A, Kennedy K, Perales-Puchalt J, Drew D, et al
    Mild-moderate CKD is not associated with cognitive impairment in older adults in the Alzheimer's Disease Neuroimaging Initiative cohort.
    PLoS One. 2020;15:e0239871.
    PubMed     Abstract available


  117. GAO Y, Sengupta A, Li M, Zu Z, et al
    Functional connectivity of white matter as a biomarker of cognitive decline in Alzheimer's disease.
    PLoS One. 2020;15:e0240513.
    PubMed     Abstract available


  118. C RC, Lukose B, Rani P
    G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer's disease pathology.
    PLoS One. 2020;15:e0225487.
    PubMed     Abstract available


  119. KUEPER JK, Lizotte DJ, Montero-Odasso M, Speechley M, et al
    Cognition and motor function: The gait and cognition pooled index.
    PLoS One. 2020;15:e0238690.
    PubMed     Abstract available


  120. YAO T, Sweeney E, Nagorski J, Shulman JM, et al
    Quantifying cognitive resilience in Alzheimer's Disease: The Alzheimer's Disease Cognitive Resilience Score.
    PLoS One. 2020;15:e0241707.
    PubMed     Abstract available


  121. YOKOSAWA K, Kimura K, Takase R, Murakami Y, et al
    Functional decline of the precuneus associated with mild cognitive impairment: Magnetoencephalographic observations.
    PLoS One. 2020;15:e0239577.
    PubMed     Abstract available


  122. AHMED S, Kim BC, Lee KH, Jung HY, et al
    Ensemble of ROI-based convolutional neural network classifiers for staging the Alzheimer disease spectrum from magnetic resonance imaging.
    PLoS One. 2020;15:e0242712.
    PubMed     Abstract available


  123. SEDGHIZADEH MJ, Hojjati H, Ezzatdoost K, Aghajan H, et al
    Olfactory response as a marker for Alzheimer's disease: Evidence from perceptual and frontal lobe oscillation coherence deficit.
    PLoS One. 2020;15:e0243535.
    PubMed     Abstract available


  124. OKUDA M, Fujita Y, Takada-Takatori Y, Sugimoto H, et al
    Aromatherapy improves cognitive dysfunction in senescence-accelerated mouse prone 8 by reducing the level of amyloid beta and tau phosphorylation.
    PLoS One. 2020;15:e0240378.
    PubMed     Abstract available


  125. GUYON A, Rousseau J, Lamothe G, Tremblay JP, et al
    The protective mutation A673T in amyloid precursor protein gene decreases Abeta peptides production for 14 forms of Familial Alzheimer's Disease in SH-SY5Y cells.
    PLoS One. 2020;15:e0237122.
    PubMed     Abstract available


  126. KIM D, Lee JH, Kim HY, Shin J, et al
    Fluorescent indolizine derivative YI-13 detects amyloid-beta monomers, dimers, and plaques in the brain of 5XFAD Alzheimer transgenic mouse model.
    PLoS One. 2020;15:e0243041.
    PubMed     Abstract available


  127. DENG Y, Wu S, Fan H
    Genome-wide pathway-based quantitative multiple phenotypes analysis.
    PLoS One. 2020;15:e0240910.
    PubMed     Abstract available


  128. LI QS, Tian C, Hinds D, Seabrook GR, et al
    The association of clinical phenotypes to known AD/FTD genetic risk loci and their inter-relationship.
    PLoS One. 2020;15:e0241552.
    PubMed     Abstract available


  129. MENTINK LJ, Thomas J, Melis RJF, Olde Rikkert MGM, et al
    Home-EEG assessment of possible compensatory mechanisms for sleep disruption in highly irregular shift workers - The ANCHOR study.
    PLoS One. 2020;15:e0237622.
    PubMed     Abstract available


  130. GREEN EH, Kikis EA
    Determining the effects of nanoparticulate air pollution on proteostasis in Caenorhabditis elegans.
    PLoS One. 2020;15:e0243419.
    PubMed     Abstract available


  131. BORGSTEDT L, Blobner M, Musiol M, Bratke S, et al
    Neurotoxicity of different amyloid beta subspecies in mice and their interaction with isoflurane anaesthesia.
    PLoS One. 2020;15:e0242989.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: